These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32393528)

  • 1. In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate.
    Tan WK; Tan ARY; Sivanandam P; Goh EJH; Yap ZP; Saburulla NF; Austin-Muttitt K; Mullins JGL; Lau AJ
    J Pharmacol Exp Ther; 2020 Aug; 374(2):295-307. PubMed ID: 32393528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro and In Silico Analyses of the Inhibition of Human Aldehyde Oxidase by Bazedoxifene, Lasofoxifene, and Structural Analogues.
    Chen S; Austin-Muttitt K; Zhang LH; Mullins JGL; Lau AJ
    J Pharmacol Exp Ther; 2019 Oct; 371(1):75-86. PubMed ID: 31289113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interspecies differences in the metabolism of methotrexate: An insight into the active site differences between human and rabbit aldehyde oxidase.
    Choughule KV; Joswig-Jones CA; Jones JP
    Biochem Pharmacol; 2015 Aug; 96(3):288-95. PubMed ID: 26032640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes.
    Uehara S; Yoneda N; Higuchi Y; Yamazaki H; Suemizu H
    Drug Metab Dispos; 2020 Jul; 48(7):580-586. PubMed ID: 32357972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of Zaleplon 5-Oxidase Activity in Mice and Humans, and Inhibition by Raloxifene.
    Tanoue C; Sugihara K; Tayama Y; Uramaru N; Watanabe Y; Ohta S; Kitamura S
    Drug Metab Lett; 2017; 10(4):278-285. PubMed ID: 28029084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats.
    Kawashima K; Hosoi K; Naruke T; Shiba T; Kitamura M; Watabe T
    Drug Metab Dispos; 1999 Mar; 27(3):422-8. PubMed ID: 10064576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Drug-Drug Interaction between Erlotinib and OSI-930 Is Mediated through Aldehyde Oxidase Inhibition.
    Tang LWT; Shi Y; Sharma R; Obach RS
    Drug Metab Dispos; 2024 Aug; 52(9):1020-1028. PubMed ID: 38889967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative characterization of AOX1 expression level and activity relationship.
    Fu C; Di L; Han X; Soderstrom C; Snyder M; Troutman MD; Obach RS; Zhang H
    Drug Metab Dispos; 2013 Oct; 41(10):1797-804. PubMed ID: 23857892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
    J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions.
    Takaoka N; Sanoh S; Okuda K; Kotake Y; Sugahara G; Yanagi A; Ishida Y; Tateno C; Tayama Y; Sugihara K; Kitamura S; Kurosaki M; Terao M; Garattini E; Ohta S
    Biochem Pharmacol; 2018 Aug; 154():28-38. PubMed ID: 29678521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
    J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
    Burotto M; Manasanch EE; Wilkerson J; Fojo T
    Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single amino acid substitution confers high cinchonidine oxidation activity comparable with that of rabbit to monkey aldehyde oxidase 1.
    Fukiya K; Itoh K; Yamaguchi S; Kishiba A; Adachi M; Watanabe N; Tanaka Y
    Drug Metab Dispos; 2010 Feb; 38(2):302-7. PubMed ID: 19910515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
    Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
    J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase.
    Coelho C; Foti A; Hartmann T; Santos-Silva T; Leimkühler S; Romão MJ
    Nat Chem Biol; 2015 Oct; 11(10):779-83. PubMed ID: 26322824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase.
    Lake BG; Ball SE; Kao J; Renwick AB; Price RJ; Scatina JA
    Xenobiotica; 2002 Oct; 32(10):835-47. PubMed ID: 12419014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.